THE WIRE · № 74094
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer
01 THE MACHINE READ
WHY IT MATTERS.
A Phase III dosing milestone for a bispecific antibody is a pipeline step, not a revenue event; approval and data readouts are years away.
Early-stage oncology pipeline news, no near-term financial impact
Interim Phase III efficacy or safety data
Trial failure or delayed enrollment
FULL DISPATCH
HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as monotherapy in...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Humana surges after topping 2027 Medicare star ratings2026-10-09 18:15 UTC
Could Menopause Hold Clues to Women's Alzheimer's Risk?2026-10-09 22:47 UTC
Alignment Healthcare Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Alignment Healthcare (ALHC)2026-10-09 22:51 UTC
The Joint Commission has Recognized Genomic Surveillance for the Detection of Transmission in Hospitals2026-10-09 23:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.